Introductionrn:rnBreast cancer is the commonest malignancy of females. It is the leading cause ofrncancer death in developing countries including Ethiopia. Chemotherapy with Adriamycin & rnCytoxan (AC) is one of the main treatment options used for breast cancer. The drugs are entirelyrnmetabolized in the liver and may influence liver function.This study is intended to assess therninfluence of these drugs on liver function, serum protein level, and hs CRP. rnObjective: The study aimed to assess the influence of chemotherapy (AC) on liver function,rnthrough determination of liver enzymes, total serum protein, serum albumin and and hs CRP rnbetween AC treated and untreated breast cancer patients at the TASH oncology unit fromrnJanuary 2020 to November 2020.rn rnPatients and methods: A comparative cross-sectional study design was used to determine liver rnenzymes (AST, ALT, ALP) , total plasma protein, albumin and serum hsCRP level between ACrnchemotherapy untreated and treated breast cancer patients. A total of 82 female breast cancerrnstudy subjects were enrolled in this study and among which 39 of them were AC untreated andrn43 of them were after taking 4rnthrn cycle of AC chemotherapy. rnResult: Mean comparison of serum liver function enzymes, hs CRP, albumin, and total proteinrnlevels among AC untreated and treated breast cancer patients showed that there was nornsignificant difference between them. Higher levels of ALP were observed among ACrnchemotheraphy untreated old age group 50-90 yrs patients than the AC treated group. Howeverrnno significant differences in the other biochemical parameters among the two groups at this age. rnConclusion: The current study didnâ€™t reveal any significant differences in the levels of liver rnfuction enzymes, total protein, albumin and hsCRP level between AC treated and untreatedrngroups. Cause a significant change in a biochemical marker of bone turnover (ALP) among oldrnage breast cancer patients.